Lefra 10 Tablet contains Leflunomide 10 mg, an immunomodulatory agent primarily indicated for the treatment of active rheumatoid arthritis and psoriatic arthritis. Leflunomide acts by inhibiting dihydroorotate dehydrogenase, a key enzyme involved in pyrimidine synthesis, thereby reducing the proliferation of activated lymphocytes responsible for the inflammatory process. This mechanism helps in decreasing joint inflammation, pain, and structural damage associated with autoimmune conditions. Lefra 10 is typically prescribed as part of a disease-modifying antirheumatic drug (DMARD) regimen to improve physical function and slow disease progression. The tablet should be administered orally, with or without food, as directed by a healthcare professional. It is essential to monitor liver function tests and blood counts periodically during therapy due to potential hepatotoxicity and hematological adverse effects. Lefra 10 is contraindicated in patients with severe hepatic impairment, pregnancy, or hypersensitivity to Leflunomide. Patients should be advised regarding potential side effects such as diarrhea, rash, alopecia, and elevated liver enzymes. Concomitant use with other immunosuppressants requires caution. Proper patient selection and monitoring can optimize therapeutic outcomes while minimizing risks associated with Lefra 10 Tablet.